UPDATED -- Benitec Biopharma Releases First Quarter 2027 Fiscal-Year Financial Results and Provides Operational Update
Key Highlights
- ➤BB-301 interim results showed 100% responder rates across Cohorts 1 and 2
- ➤BB-301 pivotal study design targeted for Q1 2027; trial remains on track for mid-2027
- ➤Cash and equivalents totaled approximately $176.5 million at September 30, 2026
- ➤Q1 FY2027 net loss widened to $12.9 million from $9.0 million
- ➤Research and development expenses rose to $8.6 million from $3.4 million
Expert Statements
Jerel A. Banks, Executive Chairman and Chief Executive Officer of Benitec Biopharma
“This has been a productive period of continued clinical progress for BB-301”
Jerel A. Banks, Executive Chairman and Chief Executive Officer of Benitec Biopharma
“We recently attended ESGCT and presented the interim clinical results for the three patients enrolled in Cohort 2 and the full clinical results for the six patients enrolled in Cohort 1 that have completed the 12-month study follow-up period.”
Jerel A. Banks, Executive Chairman and Chief Executive Officer of Benitec Biopharma
“The consistency and durability of the clinical benefit observed to date continues to strengthen our conviction in the potential of BB-301 to meaningfully alter the course of OPMD-related dysphagia.”
Jerel A. Banks, Executive Chairman and Chief Executive Officer of Benitec Biopharma
“We are grateful to the patients, families and investigators who have enabled this progress, and we look forward to confirming the pivotal study design in the first calendar quarter of 2027, with the study on track to commence in mid-2027.”
* Positive interim clinical results from the ongoing BB-301 Phase 1b/2a study for dysphagic patients with Oculopharyngeal Muscular Dystrophy (OPMD), presented as a late-breaking poster at the European Society of Gene and Cell Therapy (ESGCT) Annual Congress showed a 100% responder rate across all Cohort 1 (low dose) and Cohort 2 (high dose) patients * BB-301 pivotal study design to be finalized in the first calendar quarter of 2027, and the company remains on track to begin the pivotal trial in mid-2027 * Well-capitalized with cash, as of September 30, 2026, of approximately $176 million * Benitec plans to transition its fiscal year-end for financial reporting from June 30 to December 31. In this release, operational and program guidance is presented on a calendar-year (CY) basis, and financial guidance is presented on a June 30 fiscal-year (FY) basis HAYWARD, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage biotechnology company developing disease-modifying genetic medicines for life-threatening, genetically defined diseases, based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today announced financial results for its first fiscal quarter ended September 30, 2026, and provided an update on recent clinical data presentations.
Get started
Create a free account to read the full story.